{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T13:07:04Z","timestamp":1792242424430,"version":"4.4.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100015303","name":"Otsuka Pharmaceutical Development and Commercialization","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015303","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013327","name":"H. Lundbeck A\/S","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013327","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s40261-025-01517-9","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T13:52:13Z","timestamp":1769521933000},"page":"281-292","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy of Brexpiprazole in Participants with Agitation Associated with Dementia Due to Alzheimer\u2019s Disease: Pooled Analysis of Randomized Controlled Trials"],"prefix":"10.1007","volume":"46","author":[{"given":"Jeffrey L.","family":"Cummings","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjeda R.","family":"Chumki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malaak","family":"Brubaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanco","family":"Hefting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1905-1142","authenticated-orcid":false,"given":"Pedro","family":"Such","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George T.","family":"Grossberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,27]]},"reference":[{"issue":"3","key":"1517_CR1","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1002\/gps.5030","volume":"34","author":"R Halpern","year":"2019","unstructured":"Halpern R, Seare J, Tong J, Hartry A, Olaoye A, Aigbogun MS. Using electronic health records to estimate the prevalence of agitation in Alzheimer disease\/dementia. Int J Geriatr Psychiatry. 2019;34(3):420\u201331. https:\/\/doi.org\/10.1002\/gps.5030.","journal-title":"Int J Geriatr Psychiatry"},{"issue":"12","key":"1517_CR2","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1002\/gps.5604","volume":"36","author":"H Fillit","year":"2021","unstructured":"Fillit H, Aigbogun MS, Gagnon-Sanschagrin P, Cloutier M, Davidson M, Serra E, et al. Impact of agitation in long-term care residents with dementia in the United States. Int J Geriatr Psychiatry. 2021;36(12):1959\u201369. https:\/\/doi.org\/10.1002\/gps.5604.","journal-title":"Int J Geriatr Psychiatry"},{"issue":"9","key":"1517_CR3","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1017\/S1041610218001898","volume":"31","author":"M Anatchkova","year":"2019","unstructured":"Anatchkova M, Brooks A, Swett L, Hartry A, Duffy RA, Baker RA, et al. Agitation in patients with dementia: a systematic review of epidemiology and association with severity and course. Int Psychogeriatr. 2019;31(9):1305\u201318. https:\/\/doi.org\/10.1017\/S1041610218001898.","journal-title":"Int Psychogeriatr"},{"issue":"4","key":"1517_CR4","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1017\/S1041610222001041","volume":"36","author":"M Sano","year":"2024","unstructured":"Sano M, Cummings J, Auer S, Bergh S, Fischer CE, Gerritsen D, et al. Agitation in cognitive disorders: progress in the International Psychogeriatric Association consensus clinical and research definition. Int Psychogeriatr. 2024;36(4):238\u201350. https:\/\/doi.org\/10.1017\/S1041610222001041.","journal-title":"Int Psychogeriatr"},{"issue":"5","key":"1517_CR5","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1176\/appi.ajp.2014.14040480","volume":"172","author":"ME Peters","year":"2015","unstructured":"Peters ME, Schwartz S, Han D, Rabins PV, Steinberg M, Tschanz JT, et al. Neuropsychiatric symptoms as predictors of progression to severe Alzheimer\u2019s dementia and death: the Cache County Dementia Progression Study. Am J Psychiatry. 2015;172(5):460\u20135. https:\/\/doi.org\/10.1176\/appi.ajp.2014.14040480.","journal-title":"Am J Psychiatry"},{"key":"1517_CR6","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/j.trci.2019.10.004","volume":"5","author":"M Cloutier","year":"2019","unstructured":"Cloutier M, Gauthier-Loiselle M, Gagnon-Sanschagrin P, Guerin A, Hartry A, Baker RA, et al. Institutionalization risk and costs associated with agitation in Alzheimer\u2019s disease. Alzheimers Dement (N Y). 2019;5:851\u201361. https:\/\/doi.org\/10.1016\/j.trci.2019.10.004.","journal-title":"Alzheimers Dement (N Y)"},{"issue":"12","key":"1517_CR7","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1080\/03007995.2021.1978417","volume":"37","author":"J Schein","year":"2021","unstructured":"Schein J, Houle C, Urganus A, Cloutier M, Patterson-Lomba O, Wang Y, et al. Prevalence of post-traumatic stress disorder in the United States: a systematic literature review. Curr Med Res Opin. 2021;37(12):2151\u201361. https:\/\/doi.org\/10.1080\/03007995.2021.1978417.","journal-title":"Curr Med Res Opin"},{"key":"1517_CR8","doi-asserted-by":"publisher","DOI":"10.1177\/14713012251340463","author":"G Grossberg","year":"2025","unstructured":"Grossberg G, Willey C, Houle C, Schein J, Bungay R, Cloutier M, et al. Agitation in individuals with Alzheimer\u2019s disease: an assessment of behaviors using the Cohen-Mansfield Agitation Inventory in community-dwellers and impact on caregiver experience. Dementia (London). 2025. https:\/\/doi.org\/10.1177\/14713012251340463.","journal-title":"Dementia (London)."},{"issue":"1","key":"1517_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/bmjment-2024-301019","volume":"27","author":"W L\u00fc","year":"2024","unstructured":"L\u00fc W, Liu F, Zhang Y, He X, Hu Y, Xu H, et al. Efficacy, acceptability and tolerability of second-generation antipsychotics for behavioural and psychological symptoms of dementia: a systematic review and network meta-analysis. BMJ Ment Health. 2024;27(1):e301019. https:\/\/doi.org\/10.1136\/bmjment-2024-301019.","journal-title":"BMJ Ment Health"},{"issue":"3","key":"1517_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-007382","volume":"5","author":"S Morris","year":"2015","unstructured":"Morris S, Patel N, Baio G, Kelly L, Lewis-Holmes E, Omar RZ, et al. Monetary costs of agitation in older adults with Alzheimer\u2019s disease in the UK: prospective cohort study. BMJ Open. 2015;5(3):e007382. https:\/\/doi.org\/10.1136\/bmjopen-2014-007382.","journal-title":"BMJ Open"},{"key":"1517_CR11","doi-asserted-by":"publisher","first-page":"175","DOI":"10.2147\/cia.S69484","volume":"11","author":"JC Mill\u00e1n-Calenti","year":"2016","unstructured":"Mill\u00e1n-Calenti JC, Lorenzo-L\u00f3pez L, Alonso-B\u00faa B, de Labra C, Gonz\u00e1lez-Abraldes I, Maseda A. Optimal nonpharmacological management of agitation in Alzheimer\u2019s disease: challenges and solutions. Clin Interv Aging. 2016;11:175\u201384. https:\/\/doi.org\/10.2147\/cia.S69484.","journal-title":"Clin Interv Aging"},{"key":"1517_CR12","unstructured":"Cloak N, Schoo C, Al Khalili Y. Behavioral and psychological symptoms in dementia. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK551552\/. Accessed 29 Oct 2025."},{"issue":"6","key":"1517_CR13","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1080\/00325481.2025.2517535","volume":"137","author":"GT Grossberg","year":"2025","unstructured":"Grossberg GT, Sanford A, Montano CB, Porsteinsson AP, Scanland S, Worz C, et al. A US-based practitioner\u2019s guide to diagnosis, evaluation, and evidence-based treatment of agitation in Alzheimer\u2019s dementia\u2013recommendations of an expert, multispecialty advisory panel. Postgrad Med. 2025;137(6):469\u201385. https:\/\/doi.org\/10.1080\/00325481.2025.2517535.","journal-title":"Postgrad Med"},{"key":"1517_CR14","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.2147\/ndt.S163842","volume":"14","author":"J Masopust","year":"2018","unstructured":"Masopust J, Protopopov\u00e1 D, Vali\u0161 M, Pavelek Z, Kl\u00edmov\u00e1 B. Treatment of behavioral and psychological symptoms of dementias with psychopharmaceuticals: a review. Neuropsychiatr Dis Treat. 2018;14:1211\u201320. https:\/\/doi.org\/10.2147\/ndt.S163842.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"11","key":"1517_CR15","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1517\/14656566.2015.1059422","volume":"16","author":"IM Antonsdottir","year":"2015","unstructured":"Antonsdottir IM, Smith J, Keltz M, Porsteinsson AP. Advancements in the treatment of agitation in Alzheimer\u2019s disease. Expert Opin Pharmacother. 2015;16(11):1649\u201356. https:\/\/doi.org\/10.1517\/14656566.2015.1059422.","journal-title":"Expert Opin Pharmacother"},{"key":"1517_CR16","unstructured":"Marcan Pharmaceuticals Inc. Risperidone product monograph [Canada]. 2022. https:\/\/pdf.hres.ca\/dpd_pm\/00065018.PDF. Accessed 29 Oct 2025."},{"key":"1517_CR17","unstructured":"Accord Healthcare Limited. Risperidone summary of product characteristics [UK]. 2025. https:\/\/www.accord-healthcare-products.co.uk\/document\/smpc-risperidone-0-5mg-film-coated-tablets\/. Accessed 29 Oct 2025."},{"issue":"1","key":"1517_CR18","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1080\/14737175.2024.2407836","volume":"25","author":"K Zhong","year":"2025","unstructured":"Zhong K, Cummings J. A critical review of brexpiprazole oral tablets as the first drug approved to treat agitation symptoms associated with dementia due to Alzheimer\u2019s disease. Expert Rev Neurother. 2025;25(1):5\u201313. https:\/\/doi.org\/10.1080\/14737175.2024.2407836.","journal-title":"Expert Rev Neurother"},{"issue":"5","key":"1517_CR19","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1017\/s1092852924000427","volume":"29","author":"JL Cummings","year":"2024","unstructured":"Cummings JL, Brubaker M, Selzler KJ, Gonzalez ST, Patel M, Stahl SM. An overview of the pathophysiology of agitation in Alzheimer\u2019s dementia with a focus on neurotransmitters and circuits. CNS Spectr. 2024;29(5):316\u201325. https:\/\/doi.org\/10.1017\/s1092852924000427.","journal-title":"CNS Spectr"},{"issue":"3","key":"1517_CR20","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1124\/jpet.114.213793","volume":"350","author":"K Maeda","year":"2014","unstructured":"Maeda K, Sugino H, Akazawa H, Amada N, Shimada J, Futamura T, et al. Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin\u2013dopamine activity modulator. J Pharmacol Exp Ther. 2014;350(3):589\u2013604. https:\/\/doi.org\/10.1124\/jpet.114.213793.","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"1517_CR21","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jagp.2019.09.009","volume":"28","author":"GT Grossberg","year":"2020","unstructured":"Grossberg GT, Kohegyi E, Mergel V, Josiassen MK, Meulien D, Hobart M, et al. Efficacy and safety of brexpiprazole for the treatment of agitation in Alzheimer\u2019s dementia: two 12-week, randomized, double-blind, placebo-controlled trials. Am J Geriatr Psychiatry. 2020;28(4):383\u2013400. https:\/\/doi.org\/10.1016\/j.jagp.2019.09.009.","journal-title":"Am J Geriatr Psychiatry"},{"issue":"12","key":"1517_CR22","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1001\/jamaneurol.2023.3810","volume":"80","author":"D Lee","year":"2023","unstructured":"Lee D, Slomkowski M, Hefting N, Chen D, Larsen KG, Kohegyi E, et al. Brexpiprazole for the treatment of agitation in Alzheimer dementia: a randomized clinical trial. JAMA Neurol. 2023;80(12):1307\u201316. https:\/\/doi.org\/10.1001\/jamaneurol.2023.3810.","journal-title":"JAMA Neurol"},{"issue":"2","key":"1517_CR23","doi-asserted-by":"publisher","first-page":"520","DOI":"10.3233\/JAD-240491","volume":"102","author":"S Behl","year":"2024","unstructured":"Behl S, Slomkowski M, Chen D, Chang D, Hefting N, Lee D, et al. Brexpiprazole for the treatment of agitation associated with dementia due to Alzheimer\u2019s disease: a 12-week, active-treatment, extension trial. J Alzheimers Dis. 2024;102(2):520\u20139. https:\/\/doi.org\/10.3233\/JAD-240491.","journal-title":"J Alzheimers Dis"},{"issue":"11","key":"1517_CR24","doi-asserted-by":"publisher","first-page":"8002","DOI":"10.1002\/alz.14282","volume":"20","author":"Y Nakamura","year":"2024","unstructured":"Nakamura Y, Adachi J, Hirota N, Iba K, Shimizu K, Nakai M, et al. Brexpiprazole treatment for agitation in Alzheimer\u2019s dementia: a randomized study. Alzheimers Dement. 2024;20(11):8002\u201311. https:\/\/doi.org\/10.1002\/alz.14282.","journal-title":"Alzheimers Dement"},{"issue":"2","key":"1517_CR25","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1007\/s13142-016-0386-8","volume":"6","author":"SI Bangdiwala","year":"2016","unstructured":"Bangdiwala SI, Bhargava A, O\u2019Connor DP, Robinson TN, Michie S, Murray DM, et al. Statistical methodologies to pool across multiple intervention studies. Transl Behav Med. 2016;6(2):228\u201335. https:\/\/doi.org\/10.1007\/s13142-016-0386-8.","journal-title":"Transl Behav Med."},{"issue":"8","key":"1517_CR26","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1080\/03007995.2025.2552278","volume":"41","author":"J Stroud","year":"2025","unstructured":"Stroud J, Cummings JL, Chumki SR, Such P, Wang D, Palma AM, et al. Brexpiprazole for agitation in clinically relevant patient subgroups: a post hoc analysis of efficacy and safety in patients with agitation associated with dementia due to Alzheimer\u2019s disease. Curr Med Res Opin. 2025;41(8):1523\u201334. https:\/\/doi.org\/10.1080\/03007995.2025.2552278.","journal-title":"Curr Med Res Opin"},{"issue":"10","key":"1517_CR27","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1007\/s40263-025-01200-9","volume":"39","author":"A Shah","year":"2025","unstructured":"Shah A, Estilo A, Sheridan PL, Kalu U, Chen D, Chang D, et al. Safety and tolerability of brexpiprazole in participants with agitation associated with dementia due to Alzheimer\u2019s disease: pooled analysis of three randomized trials and an extension trial. CNS Drugs. 2025;39(10):1011\u201323. https:\/\/doi.org\/10.1007\/s40263-025-01200-9.","journal-title":"CNS Drugs"},{"key":"1517_CR28","unstructured":"Otsuka Pharmaceutical Co. Ltd. Rexulti\u00ae (brexpiprazole) prescribing information [United States]. 2025. https:\/\/www.otsuka-us.com\/media\/static\/Rexulti-PI.pdf. Accessed 29 Oct 2025."},{"issue":"9","key":"1517_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/jpm12091362","volume":"12","author":"SK Lin","year":"2022","unstructured":"Lin SK. Racial\/ethnic differences in the pharmacokinetics of antipsychotics: focusing on East Asians. J Pers Med. 2022;12(9):1362. https:\/\/doi.org\/10.3390\/jpm12091362.","journal-title":"J Pers Med"},{"issue":"7","key":"1517_CR30","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1212\/wnl.34.7.939","volume":"34","author":"G McKhann","year":"1984","unstructured":"McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer\u2019s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer\u2019s Disease. Neurology. 1984;34(7):939\u201344. https:\/\/doi.org\/10.1212\/wnl.34.7.939.","journal-title":"Neurology"},{"issue":"3","key":"1517_CR31","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"MF Folstein","year":"1975","unstructured":"Folstein MF, Folstein SE, McHugh PR. \u201cMini-mental state\u201d. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189\u201398. https:\/\/doi.org\/10.1016\/0022-3956(75)90026-6.","journal-title":"J Psychiatr Res"},{"issue":"12","key":"1517_CR32","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1212\/wnl.44.12.2308","volume":"44","author":"JL Cummings","year":"1994","unstructured":"Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44(12):2308\u201314. https:\/\/doi.org\/10.1212\/wnl.44.12.2308.","journal-title":"Neurology"},{"issue":"1","key":"1517_CR33","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1097\/00019442-200002000-00010","volume":"8","author":"S Wood","year":"2000","unstructured":"Wood S, Cummings JL, Hsu MA, Barclay T, Wheatley MV, Yarema KT, et al. The use of the Neuropsychiatric Inventory in nursing home residents. Characterization and measurement. Am J Geriatr Psychiatry. 2000;8(1):75\u201383. https:\/\/doi.org\/10.1097\/00019442-200002000-00010.","journal-title":"Am J Geriatr Psychiatry"},{"key":"1517_CR34","volume-title":"Instruction Manual for the Cohen-Mansfield Agitation Inventory (CMAI)","author":"J Cohen-Mansfield","year":"1991","unstructured":"Cohen-Mansfield J. Instruction Manual for the Cohen-Mansfield Agitation Inventory (CMAI). Rockville: The Research Institute of the Hebrew Home of Greater Washington; 1991."},{"issue":"11","key":"1517_CR35","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1176\/appi.ajgp.13.11.991","volume":"13","author":"J Rabinowitz","year":"2005","unstructured":"Rabinowitz J, Davidson M, De Deyn PP, Katz I, Brodaty H, Cohen-Mansfield J. Factor analysis of the Cohen-Mansfield Agitation Inventory in three large samples of nursing home patients with dementia and behavioral disturbance. Am J Geriatr Psychiatry. 2005;13(11):991\u20138. https:\/\/doi.org\/10.1176\/appi.ajgp.13.11.991.","journal-title":"Am J Geriatr Psychiatry"},{"issue":"3","key":"1517_CR36","doi-asserted-by":"publisher","first-page":"M77","DOI":"10.1093\/geronj\/44.3.m77","volume":"44","author":"J Cohen-Mansfield","year":"1989","unstructured":"Cohen-Mansfield J, Marx MS, Rosenthal AS. A description of agitation in a nursing home. J Gerontol. 1989;44(3):M77-84. https:\/\/doi.org\/10.1093\/geronj\/44.3.m77.","journal-title":"J Gerontol"},{"key":"1517_CR37","volume-title":"ECDEU Assessment Manual for Psychopharmacology, Revised","author":"W Guy","year":"1976","unstructured":"Guy W. ECDEU Assessment Manual for Psychopharmacology, Revised. Rockville: National Institute of Mental Health; 1976."},{"issue":"1","key":"1517_CR38","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1037\/0033-2909.112.1.155","volume":"112","author":"J Cohen","year":"1992","unstructured":"Cohen J. A power primer. Psychol Bull. 1992;112(1):155\u20139. https:\/\/doi.org\/10.1037\/0033-2909.112.1.155.","journal-title":"Psychol Bull"},{"issue":"10","key":"1517_CR39","doi-asserted-by":"publisher","first-page":"4679","DOI":"10.1007\/s10072-024-07576-8","volume":"45","author":"G Marinheiro","year":"2024","unstructured":"Marinheiro G, Dantas JM, Mutarelli A, de Almeida AM, Monteiro GA, Zerlotto DS, et al. Efficacy and safety of brexpiprazole for the treatment of agitation in Alzheimer\u2019s disease: a meta-analysis of randomized controlled trials. Neurol Sci. 2024;45(10):4679\u201386. https:\/\/doi.org\/10.1007\/s10072-024-07576-8.","journal-title":"Neurol Sci"},{"key":"1517_CR40","unstructured":"U.S. Food and Drug Administration. FDA public health advisory: deaths with antipsychotics in elderly patients with behavioral disturbances. 2005. https:\/\/psychrights.org\/drugs\/FDAantipsychotics4elderlywarning.htm. Accessed 29 Oct 2025."},{"key":"1517_CR41","doi-asserted-by":"publisher","unstructured":"Grossberg GT, Lee D, Slomkowski M, Hefting N, Chen D, Larsen KG, et al. Tackling agitation in Alzheimer\u2019s dementia: brexpiprazole phase III trial results. J Prev Alzheimers Dis. 2022;9(Suppl 1):S10\u20131. https:\/\/doi.org\/10.14283\/jpad.2022.96.","DOI":"10.14283\/jpad.2022.96"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-025-01517-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-025-01517-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-025-01517-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T04:51:55Z","timestamp":1772254315000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-025-01517-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,27]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["1517"],"URL":"https:\/\/doi.org\/10.1007\/s40261-025-01517-9","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,27]]},"assertion":[{"value":"14 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Jeffrey L. Cummings has provided consultation to Acadia, Acumen, ALZpath, Annovis, Aprinoia, Artery, Axsome, Biogen, Biohaven, BioXcel, Bristol-Myers Squibb, Eisai, Fosun, GAP Foundation, Green Valley, Janssen, Karuna, Kinoxis, Lighthouse, Lilly, Lundbeck, LSP\/eqt, Mangrove Therapeutics, Merck, MoCA Cognition, New Amsterdam, Novo Nordisk, onocC4, Optoceutics, Otsuka, Oxford Brain Diagnostics, Praxis, Prothena, ReMYND, Roche, Scottish Brain Sciences, Signant Health, Simcere, Sinaptica, T-Neuro, TrueBinding, and Vaxxinity pharmaceutical, assessment, and investment companies. He owns the copyright of the Neuropsychiatric Inventory. Sanjeda R. Chumki, Denise Chang, Zhen Zhang, and Malaak Brubaker are full-time employees of Otsuka Pharmaceutical Development & Commercialization Inc. Nanco Hefting and Pedro Such are full-time employees of H. Lundbeck A\/S. David Wang is a full-time employee of Lundbeck LLC. George T. Grossberg has received consulting fees from Acadia, Abbott, Axsome, Biogen, Bristol-Myers Squibb, BioXcel, Eisai, Karuna, Lundbeck, MapLight Therapeutics, Otsuka, and Takeda. He is on Safety Monitoring Committees for Anavex, Quince, Merck, Newron, and Oligomerix.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"No ethics approval was required for this pooled analysis of data from published clinical trials. The original trials were approved by relevant institutional review boards and independent ethics committees and were performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"This pooled analysis used data from published clinical trials. All participants and\/or their legal representatives provided written or electronic informed consent prior to the start of the original trials.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"To submit inquiries related to Otsuka clinical research, or to request access to individual participant data (IPD) associated with any Otsuka clinical trial, please visit\n                      \n                      . For all approved IPD access requests, Otsuka will share anonymized IPD on a remotely accessible data sharing platform.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors contributed to the study conception and design. Data analysis was performed by Denise Chang and Zhen Zhang. All authors critically reviewed the manuscript for intellectual content. All authors read and approved the final manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}